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Abstract
Introduction Medulloblastoma is the most frequent type
of embryonal tumor in the pediatric population, account-
ing for 20–25% of all brain tumors in children. Recently,
the suspected contribution of the Polycomb group (PcG)
genes in medulloblastoma development was described.
PcG genes play an important role in developmental
processes; they are also involved in the self-renewal of
hematopoietic and neural stem cells as well as in
malignant transformation.
Purpose In this study, we evaluated the expression of
BMI1and PCGF2, members of family of PcG genes, and
their potential target, MYC oncogene, and analyzed their
association with demographic and clinical data.
Materials and methods Thirty-one children (18 males and
13 females, aged from 0.4 to 17 years) with medulloblas-
toma were included in this study. The gene’s expression
level was measured by quantitative real-time PCR, obtained
using the two-color multiplexing technique.
Results We found that the higher expression levels of BMI1
and PCGF2 genes were associated with significantly
decreased patient survival (p=0.02 and p=0.012, respec-
tively). Significant differences between gender were found,
with a higher expression level of the PCGF2 gene observed
among females (p=0.02).
Conclusion Our analysis showed correlation between BMI1





Medulloblastoma (MB) is the most frequent type of highly
malignant tumor occurring in the pediatric population, and
despite significant advances in therapeutic modalities, it is
still associated with a high mortality rate. Due to its
frequency and aggressive behavior, a precise disease risk
stratification of patients is essential. The current estimation
of disease progression in patients with MB, based mainly
on clinical factors, seems to be insufficient. Moreover, risk
estimated on the neuropathological classification of this
tumor is still controversial, inasmuch as no unambiguous
criteria of characteristic morphological features are well-
defined [11]. Until now, a number of molecular factors
correlated with survival and predictors of outcome have
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appropriate classifiers for medulloblastoma.
Recently, the suspected contribution of the Polycomb
group (PcG) of genes, BMI1and PCGF2 (also known as
MEL18 or ZNF144), was described in MB pathogenesis
[36]. Human PcG complexes were classified into polycomb
repressive complex 1 (PRC1) and polycomb repressive
complex 2 subtypes. BMI1 and PCGF2 genes encode for
highly homologous proteins of PRC1 and have overlapping
functions in terms of development, self-renewal processes,
and cancer growth, mostly through the modification of the
chromatin structure [3, 36]. The significance of BMI1 as a
potential molecular diagnostic marker was described previ-
ously for breast and prostate cancer [10, 31]. In invasive
ductal breast cancer, its overexpression was defined as the
prognostic factor related to metastases and signaled a high
possibility of a poor outcome [23]. Recently, the signifi-
cance of BMI1 in non-small cell lung cancer expansion was
also reported, as well as its role in maintaining the function
of bronchioalveolar stem cells [4, 8]. Similar mechanisms,
including brain stem cells, were also well documented for
glioblastoma [1]. In medulloblastoma, BMI1 was found to
be overexpressed and their potential role in tumor patho-
genesis via expansion of tumor stem cells was also strongly
suggested, but studies into its probable link with patient
outcomes have not yet been conducted thoroughly [13, 25,
27].
PCGF2 was described previously as the regulator of
hematopoietic stem cell fate which downregulation intensi-
fy stem cell capability [21, 22]. The clinical value of that
gene was confirmed in breast and prostate cancers, where
negative expression of PCGF2 was correlated with the
proliferation of neoplastic cells and a worse prognosis of
patients [16, 24, 34, 35].
In addition, an inverse correlation between PCGF2 and
BMI1 expression in invasive breast cancer and breast cancer
cell lines was observed [16, 24]. Interestingly, such a link
was not reported for medulloblastoma cell lines and
overlapping functions for both genes was strongly sug-
gested in MB tumorigenesis [36]. Moreover, the negative
correlation between PCGF2 and MYC, as well as between
PCGF2 and BMI1 expression and PCGF2 downregulation
of BMI1 through MYC, was observed in human fibroblast
cell lines [15]. The MYC gene was amplified in approxi-
mately 5–10% of medulloblastomas, while overexpressed
in up to 50% of tumor samples. Such inconsistency could
be caused by altered transcriptional processes dependent on
transcriptional repressor proteins such as PcG family
members BMI1 and PCGF2 [2, 14, 20].
In this work, we evaluated the expression of BMI1,
PCGF2,a n dMYC genes to determine their potential




Thirty-one children with classic type medulloblastoma,
operated on in the Department of Neurosurgery, Polish
Mother’s Memorial Hospital Research Institute, were
included in this study. The group was comprised of 18
males and 13 females. The median age of patients at the
time of diagnosis was 8 years (range, 0.4–17 years). All
specimens were diagnosed at the Department of Molecular
Pathology and Neuropathology, Chair of Oncology, Med-
ical University of Lodz, according to the World Health
Organization criteria [26].
Based on clinical data, the patients were divided into
standard risk (SR) and high risk (HR) groups consist of 16
and 15 children, respectively. Patients under 3 years of age
at the time of diagnosis, with more than 1.5 cm
3 of residual
disease after surgery or with evidence of metastases, were
classified to HR group, while children older than 3 years of
age, with no evidence of metastatic disease and less than
1.5 cm
3 of residual disease, were stratified as SR group.
Seven patients under 3 years of age received chemother-
apy (no radiotherapy) that consisted of alternate courses of
vincristine, etoposide, and cisplatin and vincristine, etopo-
side, and cyclophosphamide during 18 months. HR patients
were treated by preirradiation chemotherapy (four alternate
courses) with vincristine, etoposide and carboplatin and
etoposide, ifosfamide, and cisplatin and maintenance chemo-
therapy with vincristine, lomustine, and cisplatin (six to eight
courses). SR patients received preirradiation chemotherapy
(four alternate courses) consisting of vincristine, etoposide and
carboplatin and vincristine, etoposide, and cyclophosphamide
and maintenance chemotherapy with vincristine, lomustine,
and cisplatin (six to eight courses). Radiotherapy was given
with total doses of 35 Gy for brain and spine and 50–55 Gy
on tumor site.
Survival periods were collected for all children. The
mean follow-up time was 58 months (in a range from 4 to
156 months). The Bioethics Medical University Committee
approved all analyses performed (no. RNN/154/06/KE).
RNA isolation
RNA was extracted using a commercially available RNeasy
Mini Kit (cat. no. 74104; Qiagen) and treated with DNAase
(cat. no. 79254; Qiagen). RNA concentrations were
measured spectrophotometrically. One microgram of total
RNA from all specimens and reference RNA (Human
Cerebellum Brain Total RNA cat. no. 6820; Ambion, USA)
was reverse-transcribed into single-stranded cDNA accord-
ing to standard protocol (cat. no. 205313; Qiagen) in two
independent reactions for each sample.
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The expression levels of target and reference genes were
measured by quantitative real-time PCR (Q-PCR), using the
2-color multiplexing technique. The Q-PCR experiment was
designed using the free web-based ProbeFinder software
version 2.41 for Human, which specifies a set of primers and
probes from the Universal ProbeLibrary (cat. no.
04688627001, BMI1; cat. no. 04687671001, MYC;c a t .n o .
04687973001, PCGF2; Roche Diagnostic GmbH, Germany)
as well as reference gene (cat. no. 05 046 157 001, HPRT;
Roche Diagnostic GmbH, Germany). The sequences of the
set of primers and numbers of probes used are listed in
Table 1. The optimized Q-PCR assay was performed in a
20 μl reaction mixture containing water, 5 μlo ft e m p l a t e
(cDNA), 10 μl FastStart TaqMan Probe Master (cat. no. 04
673 417 001; Roche Diagnostic GmbH, Germany), 500 nM
of each of the primers, and 250 nM of each of the probe.
Reactions were performed on a Rotor Gene 6000 instrument
(Qiagene-Corbett Life Science, Sydney, Australia) under the
following conditions: initial cDNA polymerase activation at
95°C for 15 min, followed by 45 cycles of 95°C for 15 s
(denaturation) and 60°C for 45 s (annealing) with multi-
channel detection. All samples were analyzed in triplicate to
obtain replicates for statistical analyses.
Statistical analysis
A normalized relative expression level for a given target
gene was calculated using the method described by Pfaffl et
al. with pooled cDNA from all tumor samples used as a
control, according to the equation,
Ratio ¼
ETARGET ðÞ
ΔCPTARGET control sample ðÞ
EREF ðÞ
ΔCPREF control sample ðÞ
where ETARGET and EREF stand for the Q-PCR efficiency of
target and reference gene amplification, respectively, and
ΔCPTARGET(control − sample) and ΔCPREF(control −
sample) denote the difference in crossing points (CP)
between unknown and control samples for a given target
and reference gene, respectively [28]. The differences in
gene expression levels were evaluated by Mann–Whitney
U. Statistical significance was assumed for p value ≤0.05.
Kaplan–Meier curves were estimated from survival data for
two groups based on the median expression level of each
gene.
Results
The clinical data, including patient’s age, sex, clinical risk,
and follow-up data, are given in Table 2. Median levels of
BMI1, MYC, and PCGF2 mRNA expression were 1.94
(range, 1.21–3.10), 3.80 (range, 1.06–53.86), and 1.79
(range, 0.98–2.45), respectively (Table 2). Significant
differences (p=0.02) between gender were found for the
PCGF2 gene, with higher expression level observed among
females (Fig. 1). The survival analysis performed following
the group stratification based on the median expression
level of each gene revealed an association between higher
expression levels of BMI1 and PCGF2 and a significantly
decreased patient survival rate (p=0.02 and p=0.012,
respectively). Estimation of outcomes, using the Kaplan–
Meier method, demonstrate a prediction of 5-year survival
rates of 35% and 65% for high and low expression levels of
the BMI1 gene, respectively (Fig. 2), and 37% and 70% for
high and low expression levels of the PCGF2 gene,
respectively (Fig. 3). Kaplan–Meier survival analysis
performed for female and male patients independently
showed better outcome for female patients with low
expression levels of the PCGF2 gene (Figs. 4 and 5).
Expression level of MYC gene was unrelated to clinical
outcome (Fig. 6). Statistical analysis revealed significant
differences in expression levels between two groups,
obtained based on the clinical risk stratification (high risk
vs. standard risk) for the MYC gene, but not for BMI1 and
PCGF2 genes. There was no significant differences in
Table 1 Sequences of primers used for gene expression analysis, with numbers of probes used
Probe/primer name Sequence (5′-3′) Position Amplicon size Reference gene assay
Probe#63 HPRT
BMI1-F TTCTTTGACCAGAACAGATTGG 888–909 112 bp
BMI1-R GCATCACAGTCATTGCTGCT 980–999
Probe#34
MYC-F CACCAGCAGCGACTCTGA 741–758 102 bp
MYC-R GATCCAGACTCTGACCTTTTGC 821–842
Probe#39
PCGF2-F TTCTCCGCAACAAGATGGAT 740–759 67 bp
PCGF2-R AGTGGCTCGTCCTCGTACA 788–806
Childs Nerv Syst (2011) 27:79–86 81expression levels of any of the genes studied between the
two age groups (under 3 years vs. over 3 years). The
analysis of correlation between genes reached the level of
statistical significance, nevertheless it showed only low
values of rank correlation coefficients obtained using
Spearman’s correlation test: MYC vs. BMI1 (r
2=0.19, p=
0.02), MYC vs. PCGF2 (r
2=0.24, p=0.005), BMI1 vs.
PCGF2 (r
2=0.26, p=0.003; Fig. 7). As indicated by
obtained coefficient of determination, the correlation
between PCGF2 and BMI1 accounted for only about 26%
of common variability of these genes’ expression (this
correlation was excluded from consideration).
Discussion
Members of the PcG gene family act as epigenetic gene
silencers and control biological processes, including self-
renewal of both normal and neoplastic stem cells. Their role
in tumorigenesis is related to the modulation of tumor
suppressor pathways, crucial for the cell cycle and
oncogenesis. A connection was observed between PcG
genes overexpression and the INK4a/ARF, Rb, and TP53
pathways silencing [10, 24]. There was also some evidence
of correlation between PcG transcriptional repressor pro-
teins and developmental pathways such as Hedgehog, Wnt/
Table 2 Clinical data of medulloblastoma
Case Age, yaers Sex Age category Clinical risk Follow-up, mo Outcome Gene relative expression level
BMI1 MYC PCGF2
M1 8 F >3 HR 24 A 2.21 3.80 1.64
M2 5 F >3 HR 18 D 2.89 53.86 2.44
M3 12 F >3 SR 37 A 2.21 2.93 1.82
M4 10 M >3 HR 39 A 1.42 1.06 0.98
M5 7 M >3 SR 40 A 1.21 2.45 1.48
M6 2 M ≤3 HR 4 D 2.16 19.52 2.34
M7 0.4 F ≤3 HR 8 D 2.22 6.97 2.26
M8 2 M ≤3 HR 15 D 2.02 3.77 1.71
M9 14 M >3 HR 60 A 1.93 11.81 1.79
M10 5 F >3 SR 16 D 2.38 2.65 2.12
M11 3 F ≤3 SR 60 A 2.38 3.52 2.11
M12 3 M ≤3 HR 30 D 2.06 10.42 1.59
M13 17 M >3 SR 78 A 1.78 1.73 1.40
M14 7 M >3 HR 81 D 1.52 2.65 1.87
M15 8 M >3 HR 7 D 1.89 30.65 1.82
M16 8 M >3 SR 81 A 1.39 1.69 1.44
M17 2 F ≤3 HR 107 A 1.50 2.68 1.52
M18 13 M >3 SR 47 D 1.94 1.95 2.45
M19 15 F >3 SR 120 A 1.78 13.54 1.88
M20 5 M >3 SR 110 A 1.78 4.16 1.61
M21 8 F >3 HR 42 D 1.71 20.94 2.24
M22 11 M >3 SR 40 D 3.10 3.28 1.92
M23 13 M >3 SR 3 D 1.26 1.11 1.27
M24 11 M >3 SR 133 D 1.98 15.42 1.51
M25 10 M >3 HR 134 D 2.66 35.46 1.80
M26 8 F >3 SR 124 A 1.65 15.71 1.61
M27 6 M >3 HR 30 D 2.86 11.36 1.41
M28 8 M >3 SR 156 A 1.79 2.90 1.67
M29 7 F >3 HR 29 D 1.99 33.33 2.16
M30 3 F ≤3 SR 2 D 1.80 1.40 1.45
M31 5 F >3 SR 120 A 2.21 11.82 1.98
Reference gene (HPRT) relative expression level 1.65 1.65 1.70
Relative gene expression level evaluated by quantitative real-time PCR performed by 2-color multiplexing technique
A alive, D deceased, F female, HR high risk, M male, SR standard risk
82 Childs Nerv Syst (2011) 27:79–86beta-catenin, and Notch considered to be essential in
medulloblastoma pathogenesis [27]. Via these pathways,
PcG genes suppressed tumor development, progression,
and expansion mainly by the limitation of putative cancer
stem cells. Their expression and potential value as clinical
biomarkers have been considered in selected types of
cancers. The most often observed alteration has been
upregulation of BMI1, which was related to a poor
prognosis in epithelial cancers and leukemias [4, 8, 23,
29, 34]. In medulloblastoma, altered expression of BMI1
was reported as well as correlation between BMI1
expression and the Hedgehog pathway activation [13, 27].
Leung et al. established the plausible significance of BMI1
in medulloblastoma pathogenesis but its clinical value has
not been well estimated until now [25]. Based on micro-
array analysis, Glinsky et al. suggested the usefulness of
BMI1 expression in prediction of outcomes in medulloblas-
toma [13]. In this work, we presented an association
between a higher expression level of BMI1 and decreased
patient survival. Estimation of outcomes using the Kaplan–
Meier method showed a trend towards a better outcome in
the group with lower expression level of the BMI1 gene.
BMI1 expression and its potential usefulness as a molecular
factor of outcomes were analyzed in brain tumors but not in
Fig. 4 Survival analysis of female patients stratified by expression of
PCGF2. Kaplan–Meier analysis of survival in 13 females with
medulloblastoma. Patients were stratified into two groups based on
median expression level. Follow-up is expressed as time from
diagnosis, in months
Fig. 3 Survival analysis of patients stratified by expression of
PCGF2. Kaplan–Meier analysis of survival in 31 children with
medulloblastoma. Patients were stratified into two groups based on
median expression level. Follow-up is expressed as time from
diagnosis, in months
Fig. 2 Survival analysis of patients stratified by expression of BMI1.
Kaplan–Meier analysis of survival in 31 children with medulloblastoma.
Patients were stratified into two groups based on their median expression
level. Follow-up is expressed as time from diagnosis, in months
Fig. 1 PCGF2 expression level according to gender. F female, M
male. Data are presented as medians with respective interquartile
ranges (IQR). Expression levels (median (IQR)) were 1.98 (1.63–
2.16) and 1.64 (1.44–1.82) for females and males, respectively
Childs Nerv Syst (2011) 27:79–86 83medulloblastoma. Tirabosco et al. and Häyry et al. found no
correlation between BMI1 expression and outcome in
astrocytomas, but such a link was observed in oligoden-
droglial tumors [18, 32]. Häyry et al., after reviewing
analysis of BMI1 loss in glial tumors, pointed out the
association of gene deletion with poor outcomes in grade
II–IV astrocytomas and considered that plausible BMI1
gene function (oncogenic or suppressing) could vary
according to the type of tumor, kind of molecular alteration,
or transcriptional events [17].
A similar phenomenon was noted for the PCGF2 gene,
which encodes a functional homologue of BMI1 and
Fig. 7 The relationship between genes obtained using Spearman’s
correlation test. a MYC vs. BMI1, r
2=0.19, p=0.02; b MYC vs.
PCGF2, r
2=0.24, p=0.005; c PCGF2 vs. BMI1, r
2=0.26, p=0.003 Fig. 6 Survival analysis of patients stratified by expression of MYC.
Kaplan–Meier analysis of survival in 31 children with medulloblastoma.
Patients were stratified into two groups based on median expression
level. Follow-up is expressed as time from diagnosis, in months
Fig. 5 Survival analysis of male patients stratified by expression of
PCGF2.K a p l a n –Meier analysis of survival in 18 males with
medulloblastoma. Patients were stratified into two groups based on
median expression level. Follow-up is expressed as time from
diagnosis, in months
84 Childs Nerv Syst (2011) 27:79–86regulates self-renewal processes in hematopoietic cells, as
does BMI1 [12, 21, 22, 36]. While in prostate and breast
tissue PCGF2 functioned as a tumor suppressor gene, there
were evidences of its oncogenic function in medulloblasto-
ma [15, 16, 34, 36]. Here, we demonstrated a link between
a higher expression level of PCGF2 and decreased patient
survival especially among females. Our results indicated the
oncogenic function of PCGF2 in human medulloblastoma
and confirmed the observation of Wiederschan et al.
obtained in experimental study of medulloblastoma cell
lines [36]. The data presented here showed also sex-
dependent gene expression of the PCGF2. The higher gene
expression in female patients may be interpreted as the
consequence of the mechanism of chromosome X inacti-
vation, induced via Xist RNA (X-inactive-specific tran-
script), in which PcG genes are involved during
development [12, 19].
In our analysis, we also included the MYC gene, which
was associated with BMI1 in oncogenic processes and in
breast cancer was repressed by PCGF2 [15, 16]. MYC
oncogene overexpression was described in approximately
50% of medulloblastomas, but its connection with progno-
sis predictions is unclear [9, 14, 20]. Rutkowski et al. and
Herms et al. revealed the relevance of MYC expression for
predicting outcomes, however Das et al. showed no
correlation between the MYC labeling index and
progress-free survival, similarly as De Bortoli et al., which
presented no such link either for expression analysis [5, 6,
20, 30]. These discrepancies may be caused by the different
criteria used in data interpretation, or the specificity of
groups analyzed, and still needs elucidation, especially as
regards the possibility of using the MYC as the therapeutic
target inducing apoptosis in medulloblastoma [7, 33]. Here,
we observed correlation between MYC expression level and
risk stratification and no such relationship for PcG genes. In
our opinion, lack of relation with clinical risk of BMI1 and
PCGF2 genes could be connected with imperfect clinical
risk classification of this tumor. Development of well-
chosen molecular markers used in multivariate risk estima-
tion together with clinical data must be concerned in case of
medulloblastoma.
In summary, our analysis suggest that BMI1 and PCGF2
genes, acting as the epigenetic silencers engaged in the self-
renewal processes of neoplastic stem cells, could be
engaged in medulloblastoma oncogenesis. Higher BMI1
and PCGF2 gene’s expression levels should be considered
as the predictors of poor clinical outcome for children with
medulloblastoma.
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